Infusion Options Recalls Ramucirumab Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling specific Ramucirumab infusion products in New York due to a lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating under the rubric, particularly given the risk of infection associated with non-sterile medical products.
Plain-English summary
Infusion Options, Inc. is recalling Ramucirumab 457 mg and 1182 mg infusion products. The recall is being conducted because of a lack of assurance of sterility for these products.
The affected products are distributed in New York only. The recall covers all lots within their expiration dates.
Consumers and healthcare providers should stop using the affected products and contact Infusion Options, Inc. for further instructions.
The recalled product
- Product
- RAMUCIRUMAB 457 MG QS 250 ML NS IVPB; AMUCIRUMAB 1182 MG QS 250 ML NS IVPB; Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
- Manufacturer
- Infusion Options, Inc.
- Category
- Drug — Infusion
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 76 recalled by Infusion Options, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 76 products in this recall →Related recalls
Same manufacturer · Infusion Options, Inc.
See all →- SevereInfusion Options Recalls Calcium Glucunate IV Bags Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Durvalumab Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Rituximab Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Fluorouracil Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Velcade Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- SevereAssurance Infusion Recalls Quadmix Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- HighAssurance Infusion Recalls TRIMIX Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Bi-Mix Injections Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls QUADMIX Vials Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls Multi-Drug Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SevereAssurance Infusion Recalls BUP 3.5MG/HYDROM 4MG/ML Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22